Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – Equities research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for shares of Monopar Therapeutics in a report issued on Thursday, September 25th. Cantor Fitzgerald also issued estimates for Monopar Therapeutics’ FY2026 earnings at ($2.79) EPS. Get Monopar Therapeutics alerts:MNPR has been the subject of a number of other research reports. Monopar Therapeutics Stock PerformanceShares of Monopar Therapeutics stock opened at $75.90 on Monday. Recommended StoriesReceive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.